To include your compound in the COVID-19 Resource Center, submit it here.

Ionis reports updated Phase III data for inotersen in FAP

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) reported updated data from the Phase III NEURO-TTR trial of inotersen (IONIS-TTRRx) in 172 patients with familial amyloidotic polyneuropathy (FAP), a form of transthyretin (TTR) amyloidosis.

On the first co-primary endpoint, 300 mg subcutaneous inotersen given 3 times every

Read the full 424 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers